Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Rapalink-1 slows tumor growth in prostate cancer

Publish date:: March 9, 2021

Key clinical point: The dual mTORC1-2 inhibitor Rapalink-1 reduced tumor growth in prostate cancer cells in a mouse model.

Major finding: Treating mice with Rapalink-1 every 6 days resulted in significantly reduced tumor growth and decreased expression of CD44 based on tumor size and Ki67 staining on lysates-matched tumor sections.

Study details: The data come from a molecular analysis of breast and prostate cancer bone metastasis using patient-derived xenografts (PDX) from 5 prostate cancer patients and 4 breast cancer patients and an organoid-based drug screen.

Disclosures: The study was supported by Grant # UL2015-7599 (KWF), # 169352 (SNSF), and # 179265 (SNSF) awarded to study coauthors. The researchers had no financial conflicts to disclose.

Citation:

La Manna F et al. Front Oncol. 2021 Feb 3. doi: 10.3389/fonc.2020.01012.

This Week's Must Reads

Consider potential cognitive complications prior to androgen deprivation therapy,

Diabetes raises risk of prostate cancer mortality in obese men,

Salivation inhibition fails to reduce radioiodine toxicity in prostate cancer,

Highest positive surgical margin predicts poor survival after prostatectomy,

Young minority men are underinformed about prostate cancer screening,

Must Reads in Prostate Cancer

Consider potential cognitive complications prior to androgen deprivation therapy,

Diabetes raises risk of prostate cancer mortality in obese men,

Salivation inhibition fails to reduce radioiodine toxicity in prostate cancer,

Highest positive surgical margin predicts poor survival after prostatectomy,

Young minority men are underinformed about prostate cancer screening,